title: Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.
abstract: Thirty-two patients with advanced epidermoid carcinoma of the esophagus were treated with ifosfamide (1.50 gm/m2 daily x 5 days) with uroprotective mesna in a phase II study. Eighteen patients were previously untreated. Of 28 evaluable patients, two (7%) had partial remissions lasting 2+ and 6+ months. Toxicity was predominantly myelosuppression with a median WBC nadir of 1.8 cells/ul. Seven patients required hospitalization for nadir sepsis. Ifosfamide has minimal activity in esophageal cancer and causes severe myelosuppression.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY.
authors.forename: D M
authors.initials: DM
authors.lastname: Nanus
authors.forename: D P
authors.initials: DP
authors.lastname: Kelsen
authors.forename: R
authors.initials: R
authors.lastname: Lipperman
authors.forename: M
authors.initials: M
authors.lastname: Eisenberger
mesh_terms: D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000188:drug therapy*; D004341:Drug Evaluation; D004938:Esophageal Neoplasms / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006403:Hematologic Tests; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
chemical_list: D007069:Ifosfamide